A phase I monotherapy study of RG7212, a first-in-class monoclonal antibody targeting TWEAK signaling in patients with advanced cancers
RG7212 的 I 期单药治疗研究，RG7212 是一种针对晚期癌症患者的 TWEAK 信号传导的同类首创单克隆抗体
期刊:Clinical Cancer Research
影响因子:10
doi:10.1158/1078-0432.CCR-14-1334
Ulrik N Lassen, Didier Meulendijks, Lilian L Siu, Vaios Karanikas, Morten Mau-Sorensen, Jan H M Schellens, Derek J Jonker, Aaron R Hansen, Mary E Simcox, Kathleen J Schostack, Dean Bottino, Hua Zhong, Markus Roessler, Suzana M Vega-Harring, Tiantom Jarutat, David Geho, Ka Wang, Mark DeMario, Glenwoo
